Boston Scientific (BSX) Plunges 10% Following Bernstein Conference Guidance Revision

Key Takeaways

• Boston Scientific shares plummeted approximately 10% following management’s announcement of reduced full-year organic growth projections to 6.5%–8% during the Bernstein Strategic Decisions Conference.
• Second quarter organic growth expectations were lowered to a modest 5%–7%, significantly below market forecasts.
• WATCHMAN procedure volumes experienced their first decline beginning in February, accompanied by softness in electrophysiology and Urology divisions.
• Shares touched a fresh 52-week low at $50.75 during intraday trading, marking a nearly 46% decline over the previous twelve months.
• Despite the selloff, the majority of Wall Street analysts maintain Buy or Overweight recommendations, with price projections spanning $60 to $90.

Boston Scientific Corp (BSX) experienced a sharp decline of approximately 10% during morning hours on May 27, following an appearance by CEO Mike Mahoney and Chief Medical Officer Dr. Janar Sathananthan at Bernstein’s 42nd Annual Strategic Decisions Conference, where they announced unexpected reductions to the company’s financial outlook.

Boston Scientific Corporation, BSX

Shares touched a new 52-week bottom at $50.75 during the session before staging a modest recovery. At last check, BSX was changing hands near $52.79, representing a decline of approximately 10% for the day.

The conference presentation, structured as a 50-minute question-and-answer session beginning around 8:00 a.m. ET, was an unexpected venue for such a significant guidance adjustment. Nevertheless, that’s precisely what unfolded.

Executive leadership reduced the full-year organic growth projection to a range of 6.5%–8%, while establishing second quarter organic growth expectations at merely 5%–7%. Both figures disappointed market participants.

The medical device manufacturer pointed to challenges across three critical business segments: electrophysiology (EP), WATCHMAN, and Urology. Most notably, WATCHMAN procedure volumes entered negative territory for the first time beginning in February — a development that particularly concerned investors monitoring this segment.

Leadership highlighted robust demand for concomitant WATCHMAN procedures while noting a significant deceleration in standalone cases. Hospital capacity limitations and reimbursement modifications are being identified as contributing factors.

Wall Street’s Response

The guidance adjustment intensified an already challenging period for analyst perspectives on BSX.

Daiwa had previously downgraded the shares to Neutral from Outperform, reducing its price objective to $60 from $83. BofA trimmed its target to $68 from $105, while maintaining a Buy recommendation.

However, not all analysts are turning bearish. Truist Securities reaffirmed a Buy rating with an $85 price objective following a separate $1.5 billion equity investment in MiRus. TD Cowen maintained its Buy rating with an $80 target. Piper Sandler held steady with its Overweight rating and $90 target.

This broad spectrum of price targets — spanning $60 to $90 — reflects the considerable uncertainty currently surrounding the stock.

Factors Pressuring Shares

Beyond the guidance revision itself, management identified tariff-related margin compression as an additional challenge. Competitive market share losses in EP also represent a growing concern.

BSX had already experienced downward pressure throughout the preceding 30 days as growth concerns intensified in the EP and WATCHMAN business lines. Today’s conference commentary simply quantified what the market had been anticipating.

The broader market offered little support. The S&P 500 and Nasdaq were trading relatively flat on the session, while the Dow Jones posted only marginal gains. BSX’s decline was company-specific.

InvestingPro analysis currently indicates BSX is trading below its Fair Value assessment. The company’s PEG ratio stands at 0.32, which generally suggests potential value for growth-focused investors.

The organization also maintains a $5 billion share repurchase authorization, with $3 billion remaining — and recently executed a $2 billion accelerated share repurchase agreement.

BSX’s FRACTURE pivotal trial for the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter achieved its primary safety and effectiveness endpoints, with enrollment of 420 patients across the United States and Europe.

The post Boston Scientific (BSX) Plunges 10% Following Bernstein Conference Guidance Revision appeared first on Blockonomi.